FiriX Therapeutics

FiriX Therapeutics is developing a new class of ferroptosis inhibitors to treat diseases caused by ischemia-reperfusion injury (IRI). Its lead candidate, FXT-001, has shown strong efficacy in preserving organ function and reducing tissue damage in preclinical models. By targeting ferroptotic cell death, FiriX aims to deliver first-in-class therapies that prevent IRI-related complications and significantly improve patient outcomes.